Pozen Wins Injunction To Block Par From Launching Generic Migraine Drug Treximet
This article was originally published in The Pink Sheet Daily
Executive Summary
A federal judge in Texas finds Pozen's patent infringement claims will likely withstand Par's challenges to validity and enforceability; Pozen received $15.4 million in Treximet royalty revenue in 2010.